EP3897706A4 - Compositions, methods and uses for eliciting an immune response - Google Patents

Compositions, methods and uses for eliciting an immune response Download PDF

Info

Publication number
EP3897706A4
EP3897706A4 EP19899994.8A EP19899994A EP3897706A4 EP 3897706 A4 EP3897706 A4 EP 3897706A4 EP 19899994 A EP19899994 A EP 19899994A EP 3897706 A4 EP3897706 A4 EP 3897706A4
Authority
EP
European Patent Office
Prior art keywords
eliciting
compositions
methods
immune response
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19899994.8A
Other languages
German (de)
French (fr)
Other versions
EP3897706A1 (en
Inventor
Freda E.-C. JEN
Kate SEIB
Evgeny SEMCHENKO
Michael Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018904887A external-priority patent/AU2018904887A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of EP3897706A1 publication Critical patent/EP3897706A1/en
Publication of EP3897706A4 publication Critical patent/EP3897706A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19899994.8A 2018-12-21 2019-12-20 Compositions, methods and uses for eliciting an immune response Pending EP3897706A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018904887A AU2018904887A0 (en) 2018-12-21 Compositions, methods and uses for eliciting an immune response
PCT/AU2019/051418 WO2020124159A1 (en) 2018-12-21 2019-12-20 Compositions, methods and uses for eliciting an immune response

Publications (2)

Publication Number Publication Date
EP3897706A1 EP3897706A1 (en) 2021-10-27
EP3897706A4 true EP3897706A4 (en) 2022-11-23

Family

ID=71100148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19899994.8A Pending EP3897706A4 (en) 2018-12-21 2019-12-20 Compositions, methods and uses for eliciting an immune response

Country Status (10)

Country Link
US (1) US20220062402A1 (en)
EP (1) EP3897706A4 (en)
KR (1) KR20210119397A (en)
CN (1) CN113453709A (en)
AU (1) AU2019410099A1 (en)
BR (1) BR112021012250A2 (en)
CA (1) CA3123887A1 (en)
MX (1) MX2021007539A (en)
SG (1) SG11202106494RA (en)
WO (1) WO2020124159A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082202B (en) * 2021-04-09 2022-05-17 青岛农业大学 Composite water-soluble animal vaccine adjuvant, vaccine and preparation method of vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260581A1 (en) * 2001-02-12 2005-11-24 Chiron Spa Gonococcal proteins and nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
US20120070457A1 (en) * 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
US20190072565A1 (en) * 2016-01-15 2019-03-07 Pierce Biotechnology, Inc. Protein preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260581A1 (en) * 2001-02-12 2005-11-24 Chiron Spa Gonococcal proteins and nucleic acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC P SKAAR ET AL: "The outer membrane localization of the Neisseria gonorrhoeae MsrA͞B is involved in survival against reactive oxygen species", PROC NATL ACAD SCI USA, 23 July 2002 (2002-07-23), pages 10108 - 10113, XP055721635, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126632/pdf/pq1502010108.pdf> [retrieved on 20200811] *
JEN FREDA E.-C. ET AL: "The Neisseria gonorrhoeae Methionine Sulfoxide Reductase (MsrA/B) Is a Surface Exposed, Immunogenic, Vaccine Candidate", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 137, XP055969545, DOI: 10.3389/fimmu.2019.00137 *

Also Published As

Publication number Publication date
US20220062402A1 (en) 2022-03-03
BR112021012250A2 (en) 2021-09-08
EP3897706A1 (en) 2021-10-27
WO2020124159A1 (en) 2020-06-25
MX2021007539A (en) 2021-09-21
CA3123887A1 (en) 2020-06-25
AU2019410099A1 (en) 2021-07-15
KR20210119397A (en) 2021-10-05
CN113453709A (en) 2021-09-28
SG11202106494RA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EP3610034A4 (en) Sample preparation methods, systems and compositions
EP3665156A4 (en) Compounds, compositions and methods
EP3661966A4 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3596118A4 (en) Methods for modulating an immune response
WO2018109170A3 (en) Il-11ra antibodies
EP3868399A4 (en) Immune composition, preparation method therefor, and application thereof
EP3676297A4 (en) Compounds, compositions and methods
WO2018109174A3 (en) Il-11 antibodies
EP3474867A4 (en) Chimeric antigen receptors (cars), compositions and methods thereof
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
EP3600325A4 (en) Novel compositions and methods
EP3615612A4 (en) Thermoplastic compositions, methods, apparatus, and uses
EP3601216A4 (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
IL283754A (en) Anti-claudin antibodies, compositions comprising same and uses thereof
EP3773718A4 (en) Compositions and methods comprising anti-nrp2 antibodies
EP3049092A4 (en) Compositions, methods and kits for eliciting an immune response
EP3113798A4 (en) Methods and compositions for modifying the immune response
EP3277313A4 (en) Agents and compositions for eliciting an immune response
EP3773658A4 (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
EP3884065A4 (en) Direct-to-library methods, systems, and compositions
EP3492491A4 (en) Mg53 mutant, and preparation method therefor and uses thereof
GB201901099D0 (en) Methods, uses and compositions
GB2576614B (en) Compositions, uses and methods
EP3609865A4 (en) Polyphenylenes, methods, and uses thereof
EP3543248A4 (en) PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061141

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221020

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20221014BHEP

Ipc: A61K 39/095 20060101AFI20221014BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240508